UBS ASSET MANAGEMENT AMERICAS LLC - PROGENICS PHARMACEUTICALS IN ownership

PROGENICS PHARMACEUTICALS IN's ticker is PGNX and the CUSIP is 743187106. A total of 155 filers reported holding PROGENICS PHARMACEUTICALS IN in Q1 2018. The put-call ratio across all filers is 0.92 and the average weighting 0.1%.

Quarter-by-quarter ownership
UBS ASSET MANAGEMENT AMERICAS LLC ownership history of PROGENICS PHARMACEUTICALS IN
ValueSharesWeighting
Q1 2020$202,704,000
-29.5%
53,343
-5.5%
0.00%
Q4 2019$287,392,000
-5.0%
56,462
-5.7%
0.00%
Q3 2019$302,668,000
+4.3%
59,875
+27.4%
0.00%
Q2 2019$290,058,000
+63.2%
47,011
+22.7%
0.00%
Q1 2019$177,745,000
+10.5%
38,3070.0%0.00%
Q4 2018$160,889,000
-33.0%
38,3070.0%0.00%
Q3 2018$240,185,000
-22.0%
38,3070.0%0.00%
Q2 2018$307,987,000
-13.7%
38,307
-20.0%
0.00%
Q1 2018$356,999,000
+51.7%
47,855
+21.0%
0.00%
Q4 2017$235,317,000
-19.2%
39,5490.0%0.00%
Q3 2017$291,080,000
+10.7%
39,549
+2.1%
0.00%
Q2 2017$262,936,000
-28.1%
38,7240.0%0.00%
Q1 2017$365,554,000
+154142.2%
38,724
+41.2%
0.00%
Q4 2016$237,000
-1.2%
27,424
-27.6%
0.00%
Q3 2016$240,000
+66.7%
37,862
+11.0%
0.00%
Q2 2016$144,000
-3.4%
34,1000.0%0.00%
Q1 2016$149,000
-28.7%
34,1000.0%0.00%
Q4 2015$209,000
-0.9%
34,100
-7.6%
0.00%
Q3 2015$211,000
-16.9%
36,900
+8.2%
0.00%
Q2 2015$254,00034,1000.00%
Other shareholders
PROGENICS PHARMACEUTICALS IN shareholders Q1 2018
NameSharesValueWeighting ↓
Broadfin Capital, LLC 8,951,169$54,871,0003.38%
Virtus ETF Advisers LLC 103,807$636,0001.75%
BKS ADVISORS, LLC 291,150$1,785,0000.92%
Piermont Capital Management Inc. 363,549$2,229,0000.71%
TUDOR INVESTMENT CORP ET AL 2,370,760$14,532,0000.41%
SEARLE & CO. 60,000$349,0000.34%
TURNER INVESTMENTS LLC 252,785$1,550,0000.32%
RICE HALL JAMES & ASSOCIATES, LLC 891,672$5,466,0000.31%
Phocas Financial Corp. 635,333$3,895,0000.30%
TFS CAPITAL LLC 398,283$2,441,0000.26%
View complete list of PROGENICS PHARMACEUTICALS IN shareholders